- Home
- NSTS vs CNTX Comparison
NSTS vs CNTX Comparison
Compare NSTS & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- CNTX
- Stock Information
- Founded
- NSTS 1921
- CNTX 2015
- Country
- NSTS United States
- CNTX United States
- Employees
- NSTS N/A
- CNTX N/A
- Industry
- NSTS Savings Institutions
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- NSTS Finance
- CNTX Health Care
- Exchange
- NSTS Nasdaq
- CNTX Nasdaq
- Market Cap
- NSTS 65.8M
- CNTX 60.7M
- IPO Year
- NSTS N/A
- CNTX 2021
- Fundamental
- Price
- NSTS $11.15
- CNTX $0.55
- Analyst Decision
- NSTS
- CNTX Strong Buy
- Analyst Count
- NSTS 0
- CNTX 5
- Target Price
- NSTS N/A
- CNTX $6.50
- AVG Volume (30 Days)
- NSTS 3.8K
- CNTX 83.5K
- Earning Date
- NSTS 05-12-2025
- CNTX 05-07-2025
- Dividend Yield
- NSTS N/A
- CNTX N/A
- EPS Growth
- NSTS N/A
- CNTX N/A
- EPS
- NSTS N/A
- CNTX N/A
- Revenue
- NSTS $8,931,000.00
- CNTX N/A
- Revenue This Year
- NSTS N/A
- CNTX N/A
- Revenue Next Year
- NSTS N/A
- CNTX N/A
- P/E Ratio
- NSTS N/A
- CNTX N/A
- Revenue Growth
- NSTS 82.49
- CNTX N/A
- 52 Week Low
- NSTS $9.37
- CNTX $0.55
- 52 Week High
- NSTS $13.32
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- NSTS 35.80
- CNTX 32.80
- Support Level
- NSTS $10.91
- CNTX $0.64
- Resistance Level
- NSTS $11.29
- CNTX $0.99
- Average True Range (ATR)
- NSTS 0.37
- CNTX 0.10
- MACD
- NSTS -0.09
- CNTX -0.02
- Stochastic Oscillator
- NSTS 15.09
- CNTX 0.02
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in our market area of Lake County, Illinois and adjacent communities.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.